Pharma
Zydus Lifesciences Ltd
ZYDUSLIFE · NSE · INE010B01027Wednesday, 9 Sept 20263:17 pm
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE21.2%
ROCE21.1%
ROE21.2%
1Y Return+25.74%
Avg. Volume1.4M
Price Chart
52-Week Range
About
Zydus Lifesciences Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹1,132
52W High / Low₹1,205 / ₹835.5
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE21.2%
1Y Return+25.74%
Day Change-1.57%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹28,592 Cr | ₹27,148 Cr | ₹23,242 Cr | ||||||||||
| Expenses | ₹20,276 Cr | ₹18,673 Cr | ₹16,183 Cr | ||||||||||
| Operating Profit | ₹8,316 Cr | ₹8,475 Cr | ₹7,058 Cr | ||||||||||
| OPM % | 29.0% | 31.0% | 30.0% | ||||||||||
| Other Income | ₹-74 Cr | ₹-7 Cr | ₹50 Cr | ||||||||||
| Depreciation | ₹1,725 Cr | ₹1,408 Cr | ₹916 Cr | ||||||||||
| Interest | ₹510 Cr | ₹439 Cr | ₹166 Cr | ||||||||||
| Profit Before Tax | ₹6,007 Cr | ₹6,621 Cr | ₹6,027 Cr | ||||||||||
| Tax | ₹1,414 Cr | ₹1,497 Cr | ₹1,354 Cr | ||||||||||
| Net Profit | ₹4,593 Cr | ₹5,124 Cr | ₹4,673 Cr | ||||||||||
| EPS (₹) | 44.9 | 50.1 | 45.0 | ||||||||||
| Dividend Payout % | — | 2% | 24% |
Financial history locked
Register freeRegister free to see 10 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹8,017 Cr | ₹7,587 Cr | ₹6,864 Cr | ₹6,123 Cr | |||||||||
| Expenses | ₹6,088 Cr | ₹5,033 Cr | ₹5,048 Cr | ₹4,107 Cr | |||||||||
| Operating Profit | ₹1,929 Cr | ₹2,554 Cr | ₹1,816 Cr | ₹2,016 Cr | |||||||||
| OPM % | 24.0% | 34.0% | 26.0% | 33.0% | |||||||||
| Depreciation | ₹555 Cr | ₹508 Cr | ₹360 Cr | ₹302 Cr | |||||||||
| Interest | ₹156 Cr | ₹123 Cr | ₹130 Cr | ₹101 Cr | |||||||||
| Net Profit | ₹990 Cr | ₹1,341 Cr | ₹1,023 Cr | ₹1,239 Cr | |||||||||
| EPS (₹) | 9.4 | 12.7 | 10.4 | 12.5 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹101 Cr | ₹101 Cr | ₹101 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹27,011 Cr | ₹23,852 Cr | ₹19,729 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹12,496 Cr | ₹3,213 Cr | ₹804 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹11,065 Cr | ₹9,523 Cr | ₹8,200 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹50,673 Cr | ₹36,689 Cr | ₹28,834 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹24,106 Cr | ₹13,134 Cr | ₹12,368 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹7,540 Cr | ₹6,412 Cr | ₹1,220 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹15,328 Cr | ₹14,451 Cr | ₹12,822 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹50,673 Cr | ₹36,689 Cr | ₹28,834 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 10 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹2,117 Cr | ₹-7,895 Cr | ₹5,807 Cr | ₹28 Cr |
| FY25 | ₹6,781 Cr | ₹-8,363 Cr | ₹1,995 Cr | ₹414 Cr |
| FY24 | ₹3,228 Cr | ₹-1,492 Cr | ₹-1,810 Cr | ₹-75 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 | ||||
| FY19 | ||||
| FY18 | ||||
| FY17 | ||||
| FY16 | ||||
| FY15 |
Cash flow history locked
Register freeRegister free to see 10 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-11Announcement under Regulation 30 (LODR)-Credit RatingBSE Filing2026-08-12Zydus Lifesciences Ltd (BOM:532321) (Q1 2027) Earnings Call Highlights: Robust 66. ...GuruFocus.com2026-08-11Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)PR Newswire2026-08-11Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)GlobeNewswire2026-06-16Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027Business Wire
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.